Principal Proposed Uses
1 Layer P, Zinsmeister AR, DiMagno EP. Effects of decreasing intraluminal amylase activity on starch digestion and postprandial gastrointestinal function in humans. Gastroenterology . 1986;91:41–8.
2 Starch blockers do not block starch digestion. Nutr Rev . 1985;43:46–8.
3 Draeger KE, Vertesy L, Grigoleit HG. Starch blockers. Lancet . 1983;1:354–5.
4 Summary of clinical study evaluating effectiveness of Phase 2™. Dr. R. Ballerini, Managing Director of Pharmeceutical Development and Service srl. Milano, Italy. On file with manufacturer, Pharmachem Laboratories, Kearny, NJ.
5 In vivo effectiveness or a starch absorption blocker in a double-blind placebo-controlled study with normal college-age subjects. Joe A. Vinson, PhD, and Donna M. Shuta, BS, Department of Chemistry University of Scranton, Scranton, PA 18510.
6 In vivo effectiveness of a starch absorption blocker in a double-blind placebo-controlled study with normal subjects. Joe A. Vinson, PhD, Donna M. Shuta, BS, and Hassan Al Kharrat, MS, Department of Chemistry, University of Scranton, Scranton, PA 18510.
7 Cerovic A, Miletic I, Konic-Ristic A et al. The dry plant extract of common bean seed (phaseoli vulgari pericarpium) does not have an affect on postprandial glycemia in healthy human subject. Bosn J Basic Med Sci. 2006;6:28-33.
8 Celleno L, Tolaini MV, D'Amore A, et al. A dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci . 2007;4:45-52.
- Reviewer: EBSCO CAM Review Board
- Review Date: 09/2014 -
- Update Date: 09/18/2014 -